MedTree’s Post

The Vizient 2024 Pharmacy Market Outlook is out now, providing insights into pharmaceutical price changes and GLP-1 agents like semaglutide & tirzepatide which are now FDA-approved to reduce cardiovascular risks in certain adults. 

New study, "Beyond the Prescription," by MAGNA Media Trials, in partnership with DeepIntent, reveals that pharmaceutical ads significantly influence patient behavior and health management. Key findings show that 63% of patients learn about new medications from these ads, and 55% discover new health conditions thanks to them. Learn more about the impact of pharmaceutical ads here: https://lnkd.in/eZJUUFQE

Medications like Ozempic and Mounjaro, that reputable pharmaceutical companies manufacture, help a lot of people. But there are also disreputable individuals who are trying to capitalize on counterfeit medications by making false claims that they can replicate results from the original FDA-approved medications. There have been several incidences where patients have had serious complications from these products. It’s strongly recommended that you only fill your prescriptions from licensed physicians, and not use medications from unfamiliar or unverified sources. Learn more about counterfeit diabetic medications at: bit.ly/3WmGIav #myAMCR #HeadlandsResearchAMCR #Diabetes #CounterfeitMedications #ImitationDrugs

On May 20th, the National Medical Products Administration (NMPA) announced the recent approval of a Class 1 innovative drug, "Pregabalin Benzenesulfonate Capsules" (trade name: Simening), submitted by Haisco Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Haisco"). This medication is used for the treatment of adult diabetic peripheral neuropathic pain. According to the NMPA, Pregabalin Benzenesulfonate is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The approval of this drug provides a new treatment option for adult patients suffering from diabetic peripheral neuropathic pain. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical

An excellent resource for a common counselling topic: how to use heat for muscle pain.

How are prescription drug prices determined? In the world of healthcare, few topics spark as much debate and confusion as prescription drug pricing. Have you ever wondered why that little pill in your medicine cabinet costs so much? Let’s dive into the intricate world of pharmaceutical economics and uncover the factors that determine the price tags on our prescriptions. https://lnkd.in/e7XRxAyb

Almost 300 Pharmaceutical Benefits Scheme (PBS) medicines are now available for 60-day prescriptions: https://lnkd.in/gRdYGgZT Prescribers can make the clinical decision about whether 60-day prescriptions are appropriate for patients with stable ongoing health conditions. Where a 60-day prescription is appropriate for a patient, it may reduce both time spent in consultations to renew prescriptions and the patient's annual medication costs. The Cheaper Medicines Information Kit for prescribers has more detail: https://lnkd.in/gyzbBCSd

The Pharmaceutical Care Management Association (PCMA) released the following statement on the inclusion of substantial, misguided policies targeting prescription drug benefits, in both Medicare and the commercial marketplace, in the text of a proposed government funding package. https://lnkd.in/eiv9E9xY

PROS AND CONS OF US PATIENT ORGANIZATIONS As much as #patient engagement is of course applaudable and should happen at every stage, primarily at #prevention, there are also risks by #patientorganizations blindly applauding to pseudo-innovations. This has recently happened with #Alzheimer drugs and other patient organizations in the US. Here is another example: This #MJFF is an example where supposedly #patientengagement can go wrong. Obviously there is no scientific competence and critical thinking in this foundation, e.g., where the shortcomings in the current medication and the scientific process are, and where the field is really going. This foundation applauds 60-year-old drugs when they are slightly reformulated. This is absolutely ridiculous. And the “bustling pipeline,” if you look further, are again reformulations of 60-year-old Dopa/Carbidopa. This foundation is a massive failure. 👉🏻 Please follow the interesting discussion below with Marcos Mengual Hinojosa.

The Journal of Managed Care & Specialty Pharmacy published an article predicting some of the next pharmaceutical #medications to appear on Medicare's drug negotiation list. They include medications for cancer, diabetes, GI disorders, and more. Read below. #Medicare #healthinsurance